Background Benign multiple sclerosis (MS), characterised by minimal disability despite long disease duration, remains poorly understood in terms of its determinants and prognostic implications. While ...

Sanofi to present new data from 14 abstracts across multiple sclerosis at ECTRIMS 2025 congress in Barcelona, Spain ...

BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in the EU and ...

Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi is conducting a Phase 3 clinical study titled ...

Bengaluru: Neurologists in Bengaluru are now seeing at least two to five cases of multiple sclerosis (MS) each month at ...

CET/CESTThe issuer is solely responsible for the content of this announcement.Immunic to Participate in Investor and Scientific Conferences in SeptemberNEW YORK, September 4, 2025 – Immunic, Inc.

Clene (NASDAQ: CLNN), together with its wholly owned subsidiary, Clene Nanomedicine Inc., is advancing its lead candidate CNM-Au8®, a unique and needed oral treatment for amyotrophic lateral sclerosis ...

Metformin boosts human oligodendrocyte differentiation and myelination across stem-cell, organoid, and chimera models. The study links these effects to mitochondrial metabolic shifts, supporting its ...

Clene (NASDAQ: CLNN) , together with its wholly owned subsidiary, Clene Nanomedicine Inc., is advancing its lead candidate CNM-Au8®, a unique and nee ...

The Emirates Drug Establishment has announced the approval of “Tolebrutinib” as the world’s first oral treatment for non-relapsing secondary progressive multiple sclerosis (SPMS).